Amylin Pharmaceuticals — Proxy Contest (May 2009)
33 slides from Amylin Pharmaceuticals's proxy contest presentation, May 5, 2009
Slide 1: Schedule 14A Proxy Statement Cover
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy
Slide 2: Amylin Pharmaceuticals: The Case for Change
Amylin Pharmaceuticals: The Case for Change Eastbourne Capital Management, L.L.C. May 2009
Slide 3: Disclaimer
Disclaimer This presentation is for general information purposes only. It is not intended to, and does not, address the specific investment objectives, financial situation, suitability or the particular needs of any person who may receive this presentation, and should not be taken as advice on the m
Slide 4: We Believe The Amylin Board Needs Change Now
We Believe The Amylin Board Needs Change Now Shareholders Have Lost Over $5 Billion In Shareholder Value Under The Watch Of The Current Board And Management Team • We believe the current Board and management have failed shareholders – They have failed to maximize the commercial value of the exenatid
Slide 5: Incumbent Board Presided Over Massive Loss Of Shareholder Value
The Incumbent Board Has Presided Over A Period Characterized By A Massive Loss Of Shareholder Value • Amylin’s shares have fallen over 75% since their peak of $51.43 in 2007, and now trade at $11.25 – below the 1992 IPO share price of $14.00 • The AMEX Biotech Index, on the other hand, has declined
Slide 6: Byetta's Potential Was Reflected In Wall Street Revenue Estimates
Byetta’s Enormous Potential Was Initially Reflected In Wall Street’s Revenue Estimates Bloomberg Mean Estimates of Amylin Revenues $2,200 $2,000 2010 Historical Mean Estimate $1,800 • We believe the Company’s failure to execute its $1,600 2009 Historical commercial program, control costs and prepare
Slide 7: Byetta Prescriptions Have Stalled While Competitors' Increase
Byetta Prescriptions Have Stalled While Competitors’ Increase • Byetta prescriptions growth slowed significantly at the end of 2006 with new (NRx) Byetta prescriptions only up 2% in Q406 versus Q306, a full year before the first FDA pancreatitis alert in October 2007 • Six out of the last nine quart
Slide 8: Is An "Evolution" In The Market Really The Problem?
Is An “Evolution” In The Market Really The Problem? “That is a great question, Kevin. So the question was could I comment on sensitivity to sales force size on the marketing and sales of Byetta. That is a great question we are actually looking at that at this time. Previously work that we did demons
Slide 9: We Question The Assumptions Management Is Operating Under
We Question The Assumptions Management Appears To Be Operating Under • Mr. Bradbury has expressed his judgment Total Prescriptions (TRx) Per Day (which we assume is shared by his 45,000 LANTUS management team) that there has been an 40,000 evolution over the last nine months in the +8.7% diabetes ma
Slide 10: Board And Management Have Not Addressed Lack Of Revenue Growth
Amylin Board And Management Have Not Succeeded In Addressing The Lack Of Revenue Growth While Losses Increase Annual Operating Loss 2005-2008 $0 ($50) ($100) ($150) ($200) ($209) ($250) ($237) ($243) • Operating losses increase as revenue stagnates ($300) ($297)* ($350) • Management missed its initi
Slide 11: Amylin's SG&A Spend Has Lowest Returns Among Peers
Amylin’s SG&A Spend Has Lowest Returns Among Its Peer Group Amylin SG&A and Scripts TRx Performance Amylin and Peer Group Revenue Per SG&A Dollar Spent $140,000 760,000 $8 740,000 $7 $120,000 $6 720,000 $100,000 $5 700,000 $80,000 $4 680,000 $3 $60,000 660,000 $2 $40,000 640,000 $1 $20,000 $0 620,00
Slide 12: Eli Lilly Co-Promotion Amendment Has Not Delivered Positive Change
Last Year’s Amendment To The Eli Lilly Co-Promotion Agreement Has Not Delivered Positive Change • Scripts and productivity* have declined since amending the co-promotion agreement (Q208) Field Force Productivity with Eli Lilly and increasing Amylin sales 15.0% representatives by ~15% 10.0% Sales For
Slide 13: Management's Sales Strategy Is Not Working
We Believe Management’s Sales Strategy Is Not Working And The Board Has Not Addressed This Failure Byetta, Lantus, Januvia (TRx) YoY Growth 120% 101% 93% 100% 74% 80% 70% 55% 53% 60% Byetta’s year-over-year total 46% 42% 41% scripts are weakening while 40% 36% competitors’ scripts continue to grow 2
Slide 14: Share Price Plummets After FDA Pancreatitis Alert Statements
Amylin’s Share Price Plummets In The Wake of Management’s Statements To Provide “Context And Clarity” About The FDA’s Pancreatitis Alert • Instead of providing promised clarity, we believe Amylin management’s handling of the pancreatitis alert only created greater confusion and concern August 18, 20
Slide 15: Amylin's "5 Point Plan" Lacks A Roadmap
We Believe Amylin’s “5 Point Plan” Lacks A Roadmap (1) Byetta – Return the product to growth – What specific steps will management take to achieve this given scripts have been flat for the last 2.5 years despite multiple initiatives? (2) Exenatide Once-Weekly – Position for launch – What specific st
Slide 16: Ted Greene, Co-Founder, Speaks His Mind
Ted Greene, Co-Founder Ex-Board Member Of Amylin Speaks His Mind • On April 7, 2009 Ted Greene, Co-Founder of Amylin and Board member, resigned from the Board after 22 years of service and explained his decision to resign in a publicly available letter to the Board, in which he states – “…the obviou
Slide 17: Board Had "No Clue" About "Proxy Puts" In Debt Agreements
Amylin’s Board And Management Had “No Clue” About The “Proxy Puts” Embedded In Their Debt Agreements “It was only through the internal distribution at Amylin of [a] February 2, 2009 Morgan Stanley analyst report that Amylin’s senior executives and directors learned of the existence of a Proxy Put em
Slide 18: Board's Latest Action Is Too Little Too Late
In Response To Shareholder Activism, We Think The Incumbent Board’s Latest Action Is Too Little Too Late • Amylin proposes new Directors following Eastbourne and Icahn notices of nominations – Paul N. Clark and Paulo F. Costa were added as new nominees on Amylin’s slate and we have no objection to t
Slide 19: Exenatide Program Is A Promising Therapy In GLP-1 Class
Amylin’s Exenatide Program (Byetta) Is A Promising Therapy With Significant Potential In The GLP-1 Drug Class $20.0 GLP-1 Analogs Worldwide Diabetes Drug Sales By Drug Class ($Bn) $18.0 CY2008A CY2013E $16.0 $14.0 Overall diabetes therapeutic market is expected to grow at a $12.0 compound annual gro
Slide 20: Exenatide Once-Weekly Has A Head Start, Needs A Successful Launch
Exenatide Once-Weekly Has A Head Start It Needs A Successful Launch “[Exenatide Once-Weekly has] arguably the best responses that have ever been seen with a glucose lowering therapy in the history of mankind… [the weight loss and A1c control] combination is the kind of stuff that makes clinical inve
Slide 21: Expect Exenatide Once-Weekly To Demonstrate Superiority
We Expect Exenatide Once-Weekly To Demonstrate Superiority To Most Products On The Market • Superior reduction in HbA1c • Superior weight-loss benefits DURATION Comparison Result DURATION-1 Exenatide Once-Weekly LAR reduction in HbA1c -1.9%, BYETTA reduction-1.5%; Demonstrate superiority (LAR) vs. B
Slide 22: Eastbourne's Nominees Would Add Complementary Skills
Eastbourne’s Nominees Would Add Complementary Skills To The Board Eastbourne’s Nominees as a group: • Relevant industry experience • Track records in implementing successful commercial strategies in the industry • Operational efficiencies expertise at similar companies • A track record of building a
Slide 23: Nominees Deliver Combination Of Expertise And Experience
Eastbourne’s Nominees Deliver A Combination Of Expertise And Experience Kathleen Behrens – Experienced venture capitalist and founder of multiple life-science companies – Protein Design Labs, COR Therapeutics – Former Managing Director at Robertson Stephens and RS Investments – Former Director of Ab
Slide 24: Nominees Committed To Maximizing Commercial Potential Of Products
Eastbourne's Nominees Are Committed To Maximizing The Commercial Potential Of Amylin’s Products • Eastbourne’s nominees, if elected, will encourage the Board to objectively re-assess Amylin’s current strategy: – Current sales and marketing strategy to grow Byetta prescriptions – Current strategy to
Slide 25: Board Has Failed To Deliver On Their Own Business Model
We Believe Amylin’s Board And Management Have Failed To Deliver On Their Own Business Model “The reward for doing it well is the privilege to do it again.” Joe Cook, Chairman and Then-CEO, Amylin’s 2000 Annual Report (Emphasis Supplied) We Believe Amylin’s Current Board Has Not Earned The “Privilege
Slide 26: A Vote For Eastbourne's Nominees Is A Vote To Replace Five Incumbents
A Vote For Eastbourne’s Nominees Is Also A Vote To Replace Five Incumbent Directors Eastbourne will, in connection with the proxies it receives, seek authorization to vote for all Amylin’s nominees other than the following five members of Management’s slate: Joe Cook Chairman (Since 1998), Director
Slide 27: Appendix
Appendix
Slide 28: Eastbourne Capital Management, L.L.C.
Eastbourne Capital Management, L.L.C. • Eastbourne is a research-intensive, long-term investor – Manages a concentrated portfolio with a few large investments • Owner-oriented approach to investing – Partner/employee capital comprise ~13% of firm’s funds – Often one of the largest shareholders in ea
Slide 29: Ted Greene's Letter To Amylin's Board of Directors
Ted Greene’s Letter To Amylin’s Board of Directors April 7, 2009 To my fellow Board members: I hereby resign from our Board of Directors, ending my 22 years of service to Amylin Pharmaceuticals. A majority of you decided we could not win our proxy fight if we did not replace two ex-CEO Board members
Slide 30: Amylin's Poor Compensation Practices Compared With Performance
Amylin’s Poor Compensation Practices Compared With Performance Pay for poor performance Glass, Lewis & Co. Mr. Bradbury continues to reap the benefits as CEO “…executive compensation received a D grade… in our proprietary pay-for-performance model…” • March 2007 Compensation Decision “Nominee WILSON
Slide 31: Board Moves The Goalposts With Performance Options
Amylin’s Board Moves The Goalposts With Performance Options The Board Rewards Management for Missed “Internal” Goal – In November 2007, Mr. Bradbury, along with the Company’s CFO and the head of Human Resources, met with us and told us that it was Amylin’s goal to file the NDA for Exenatide Once- We
Slide 32: Did Management Really "Voluntarily" Waive A Bonus?
Did Management Really “Voluntarily” Waive A Bonus? • ‘Cash Bonus Plan’ Goals for FY2008 (summarized from 2009 DEF14A) Corporate Goal Portion of Bonus (%) Actual FY2008 Performance Byetta prescriptions declined throughout 2008 and Product Revenue 50% overall revenue came in under management’s guidanc
Slide 33: Board Should Have Limited CEO's Outside Commitments
We Believe The Board Should Have Limited Mr. Bradbury’s Outside Commitments And Responsibilities While serving as CEO of Amylin, Mr. Bradbury has served concurrently on the governing bodies of at least seven outside organizations • The Board of Directors of – Illumina, Inc. – Chair of Audit Committe